{"id":"dabrafenib-plus-trametinib","safety":{"commonSideEffects":[{"effect":"Pyrexia","drugRate":"58.3%","placeboRate":"","totalAtRisk":1725,"totalAffected":1005,"trialsReporting":10},{"effect":"Fatigue","drugRate":"34.4%","placeboRate":"","totalAtRisk":1725,"totalAffected":594,"trialsReporting":10},{"effect":"Headache","drugRate":"34.0%","placeboRate":"","totalAtRisk":1725,"totalAffected":586,"trialsReporting":10},{"effect":"Nausea","drugRate":"32.5%","placeboRate":"","totalAtRisk":1725,"totalAffected":560,"trialsReporting":10},{"effect":"Diarrhoea","drugRate":"31.0%","placeboRate":"","totalAtRisk":1725,"totalAffected":535,"trialsReporting":10},{"effect":"Chills","drugRate":"29.6%","placeboRate":"","totalAtRisk":1725,"totalAffected":511,"trialsReporting":10},{"effect":"Arthralgia","drugRate":"25.0%","placeboRate":"","totalAtRisk":1725,"totalAffected":431,"trialsReporting":10},{"effect":"Rash","drugRate":"24.5%","placeboRate":"","totalAtRisk":1725,"totalAffected":422,"trialsReporting":10},{"effect":"Vomiting","drugRate":"24.2%","placeboRate":"","totalAtRisk":1725,"totalAffected":418,"trialsReporting":10},{"effect":"Cough","drugRate":"19.5%","placeboRate":"","totalAtRisk":1725,"totalAffected":337,"trialsReporting":10},{"effect":"Asthenia","drugRate":"18.4%","placeboRate":"","totalAtRisk":1725,"totalAffected":317,"trialsReporting":10},{"effect":"Myalgia","drugRate":"16.1%","placeboRate":"","totalAtRisk":1725,"totalAffected":277,"trialsReporting":10},{"effect":"Hypertension","drugRate":"15.0%","placeboRate":"","totalAtRisk":1725,"totalAffected":258,"trialsReporting":10},{"effect":"Oedema peripheral","drugRate":"14.4%","placeboRate":"","totalAtRisk":1725,"totalAffected":249,"trialsReporting":10},{"effect":"Alanine aminotransferase increased","drugRate":"13.5%","placeboRate":"","totalAtRisk":1725,"totalAffected":233,"trialsReporting":10},{"effect":"Aspartate aminotransferase increased","drugRate":"13.0%","placeboRate":"","totalAtRisk":1725,"totalAffected":225,"trialsReporting":10},{"effect":"Pain in extremity","drugRate":"12.5%","placeboRate":"","totalAtRisk":1725,"totalAffected":215,"trialsReporting":10},{"effect":"Decreased appetite","drugRate":"12.2%","placeboRate":"","totalAtRisk":1725,"totalAffected":211,"trialsReporting":10},{"effect":"Constipation","drugRate":"12.1%","placeboRate":"","totalAtRisk":1725,"totalAffected":209,"trialsReporting":10},{"effect":"Dry skin","drugRate":"11.5%","placeboRate":"","totalAtRisk":1725,"totalAffected":198,"trialsReporting":10},{"effect":"Influenza like illness","drugRate":"11.0%","placeboRate":"","totalAtRisk":1725,"totalAffected":189,"trialsReporting":10},{"effect":"Blood creatine phosphokinase increased","drugRate":"15.1%","placeboRate":"","totalAtRisk":1249,"totalAffected":189,"trialsReporting":8},{"effect":"Back pain","drugRate":"10.0%","placeboRate":"","totalAtRisk":1725,"totalAffected":172,"trialsReporting":10},{"effect":"Dizziness","drugRate":"9.7%","placeboRate":"","totalAtRisk":1725,"totalAffected":167,"trialsReporting":10},{"effect":"Abdominal pain","drugRate":"9.6%","placeboRate":"","totalAtRisk":1725,"totalAffected":165,"trialsReporting":10},{"effect":"Pruritus","drugRate":"9.4%","placeboRate":"","totalAtRisk":1725,"totalAffected":163,"trialsReporting":10},{"effect":"Erythema","drugRate":"9.3%","placeboRate":"","totalAtRisk":1725,"totalAffected":161,"trialsReporting":10},{"effect":"Muscle spasms","drugRate":"9.0%","placeboRate":"","totalAtRisk":1684,"totalAffected":151,"trialsReporting":9},{"effect":"Neutropenia","drugRate":"8.5%","placeboRate":"","totalAtRisk":1722,"totalAffected":147,"trialsReporting":9},{"effect":"Dyspnoea","drugRate":"8.5%","placeboRate":"","totalAtRisk":1725,"totalAffected":146,"trialsReporting":10},{"effect":"Nasopharyngitis","drugRate":"12.4%","placeboRate":"","totalAtRisk":1173,"totalAffected":145,"trialsReporting":9},{"effect":"Blood alkaline phosphatase increased","drugRate":"7.6%","placeboRate":"","totalAtRisk":1725,"totalAffected":131,"trialsReporting":10},{"effect":"Oropharyngeal pain","drugRate":"7.6%","placeboRate":"","totalAtRisk":1725,"totalAffected":131,"trialsReporting":10},{"effect":"Abdominal pain upper","drugRate":"7.3%","placeboRate":"","totalAtRisk":1725,"totalAffected":126,"trialsReporting":10},{"effect":"Dermatitis acneiform","drugRate":"10.2%","placeboRate":"","totalAtRisk":1089,"totalAffected":111,"trialsReporting":8},{"effect":"Epistaxis","drugRate":"8.9%","placeboRate":"","totalAtRisk":1173,"totalAffected":104,"trialsReporting":9},{"effect":"Urinary tract infection","drugRate":"8.4%","placeboRate":"","totalAtRisk":1173,"totalAffected":98,"trialsReporting":9},{"effect":"Dry mouth","drugRate":"8.4%","placeboRate":"","totalAtRisk":1132,"totalAffected":95,"trialsReporting":8},{"effect":"Alopecia","drugRate":"7.7%","placeboRate":"","totalAtRisk":1173,"totalAffected":90,"trialsReporting":9},{"effect":"Anaemia","drugRate":"10.2%","placeboRate":"","totalAtRisk":738,"totalAffected":75,"trialsReporting":8},{"effect":"Lipase increased","drugRate":"10.9%","placeboRate":"","totalAtRisk":679,"totalAffected":74,"trialsReporting":4},{"effect":"Rash maculo-papular","drugRate":"6.1%","placeboRate":"","totalAtRisk":1173,"totalAffected":72,"trialsReporting":9},{"effect":"Hyperkeratosis","drugRate":"9.7%","placeboRate":"","totalAtRisk":731,"totalAffected":71,"trialsReporting":7},{"effect":"Vision blurred","drugRate":"5.8%","placeboRate":"","totalAtRisk":1173,"totalAffected":68,"trialsReporting":9},{"effect":"Hyperhidrosis","drugRate":"6.0%","placeboRate":"","totalAtRisk":1129,"totalAffected":68,"trialsReporting":7},{"effect":"Palmar-plantar erythrodysaesthesia syndrome","drugRate":"5.9%","placeboRate":"","totalAtRisk":1132,"totalAffected":67,"trialsReporting":8},{"effect":"Pain","drugRate":"5.4%","placeboRate":"","totalAtRisk":1246,"totalAffected":67,"trialsReporting":7},{"effect":"Night sweats","drugRate":"6.3%","placeboRate":"","totalAtRisk":1045,"totalAffected":66,"trialsReporting":6},{"effect":"Hyperglycaemia","drugRate":"5.9%","placeboRate":"","totalAtRisk":1081,"totalAffected":64,"trialsReporting":8},{"effect":"Dysgeusia","drugRate":"5.5%","placeboRate":"","totalAtRisk":1132,"totalAffected":62,"trialsReporting":8}]},"_chembl":null,"_fixedAt":"2026-03-30T11:30:23.032500","allNames":"dabrafenib plus trametinib","_dailymed":null,"mechanism":{"target":"BRAF, MEK","drugClass":"BRAF inhibitor, MEK inhibitor","explanation":"Dabrafenib targets the BRAF V600E mutation, while trametinib inhibits MEK, both part of the MAPK pathway, which is often overactive in certain cancers. Together, they effectively block the pathway, slowing or stopping cancer cell growth.","oneSentence":"Dabrafenib and trametinib inhibit the BRAF and MEK enzymes, respectively, disrupting the MAPK signaling pathway to prevent tumor growth."},"_scrapedAt":"2026-03-28T01:47:42.261Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T08:45:49.749565+00:00","fieldsConflicting":0,"overallConfidence":0.95},"_fixedFields":["pubmed(272)","modality→Small Molecule"],"trialDetails":[{"nctId":"NCT01989585","phase":"PHASE1, PHASE2","title":"Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-03-24","conditions":"Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Malignant Solid Neoplasm","enrollment":75},{"nctId":"NCT07485569","phase":"PHASE1","title":"Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial","status":"NOT_YET_RECRUITING","sponsor":"Radboud University Medical Center","startDate":"2026-06-01","conditions":"Thyroid Cancer Stage IV, Anaplastic Thyroid Cancer, Differentiated Thyroid Cancer","enrollment":10},{"nctId":"NCT03919071","phase":"PHASE2","title":"Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-02-20","conditions":"Anaplastic Astrocytoma, Anaplastic Astrocytoma, Not Otherwise Specified, Anaplastic Ganglioglioma","enrollment":58},{"nctId":"NCT02465060","phase":"PHASE2","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-08-17","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma","enrollment":6452},{"nctId":"NCT04557956","phase":"PHASE1, PHASE2","title":"Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-08-19","conditions":"Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma","enrollment":16},{"nctId":"NCT04439292","phase":"PHASE2","title":"Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-08-12","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm","enrollment":35},{"nctId":"NCT06475989","phase":"PHASE3","title":"Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2024-08-22","conditions":"Refractory Differentiated Thyroid Gland Carcinoma","enrollment":264},{"nctId":"NCT03244956","phase":"PHASE2","title":"Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer","status":"COMPLETED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2017-12-27","conditions":"Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation","enrollment":40},{"nctId":"NCT02693535","phase":"PHASE2","title":"TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer","status":"RECRUITING","sponsor":"American Society of Clinical Oncology","startDate":"2016-03-14","conditions":"Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors","enrollment":4200},{"nctId":"NCT03091257","phase":"PHASE1","title":"A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2017-06-21","conditions":"Multiple Myeloma","enrollment":30},{"nctId":"NCT07110246","phase":"PHASE2","title":"Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2025-11-07","conditions":"BRAF V600 Mutation, Low-grade Glioma, Low Grade Glioma of Brain","enrollment":96},{"nctId":"NCT04527549","phase":"PHASE2","title":"Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma","status":"TERMINATED","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2021-06-01","conditions":"Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8","enrollment":5},{"nctId":"NCT07448480","phase":"","title":"Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"Blokhin's Russian Cancer Research Center","startDate":"2026-02-01","conditions":"Recurrent Malignant Glioma, Glioblastoma, Anaplastic Astrocytoma","enrollment":1000},{"nctId":"NCT07440290","phase":"PHASE2, PHASE3","title":"DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.","status":"NOT_YET_RECRUITING","sponsor":"Cancer Research UK","startDate":"2026-02","conditions":"Haematological Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders","enrollment":30},{"nctId":"NCT04675710","phase":"PHASE2","title":"Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-06-24","conditions":"Thyroid Gland Anaplastic Carcinoma, Thyroid Gland Squamous Cell Carcinoma","enrollment":30},{"nctId":"NCT07419932","phase":"","title":"Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer","status":"RECRUITING","sponsor":"Fujian Medical University","startDate":"2025-12-23","conditions":"Thyroid Cancer, Thyroid Neoplasms","enrollment":120},{"nctId":"NCT04666272","phase":"","title":"Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2020-12-31","conditions":"Melanoma","enrollment":78},{"nctId":"NCT02224781","phase":"PHASE3","title":"Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-09-08","conditions":"Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma","enrollment":267},{"nctId":"NCT03975829","phase":"PHASE4","title":"Pediatric Long-Term Follow-up and Rollover Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2019-11-04","conditions":"Diffuse Astrocytoma, Anaplastic Astrocytoma, Astrocytoma","enrollment":163},{"nctId":"NCT02231775","phase":"PHASE2","title":"Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2014-10-22","conditions":"Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7","enrollment":58},{"nctId":"NCT04903119","phase":"PHASE1","title":"Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma","status":"RECRUITING","sponsor":"Rina Plattner","startDate":"2022-06-01","conditions":"Metastatic Melanoma, BRAF Gene Mutation","enrollment":30},{"nctId":"NCT04201457","phase":"PHASE1, PHASE2","title":"A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pediatric Brain Tumor Consortium","startDate":"2020-01-17","conditions":"Low Grade Glioma (LGG) of Brain With BRAF Aberration, High Grade Glioma (HGG) of the Brain With BRAF Aberration, Low Grade Glioma of Brain With Neurofibromatosis Type 1","enrollment":57},{"nctId":"NCT04452877","phase":"PHASE2","title":"A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-08-19","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":40},{"nctId":"NCT06262919","phase":"","title":"Special Drug Use-results Surveillance of Tafinlar/Mekinist","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-02-09","conditions":"BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor","enrollment":110},{"nctId":"NCT04294160","phase":"PHASE1","title":"A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-07-22","conditions":"BRAF V600 Colorectal Cancer","enrollment":122},{"nctId":"NCT04489433","phase":"","title":"Compassionate Use Program to Access Trametinib and Dabrafenib for Patients With BRAF Mutation-positive Metastatic Melanoma","status":"NO_LONGER_AVAILABLE","sponsor":"Novartis Pharmaceuticals","startDate":"","conditions":"Melanoma","enrollment":""},{"nctId":"NCT05868629","phase":"","title":"Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-02-06","conditions":"Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors","enrollment":40},{"nctId":"NCT02910700","phase":"PHASE2","title":"Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-12-09","conditions":"Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7","enrollment":52},{"nctId":"NCT01972347","phase":"PHASE2","title":"Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Melanoma Institute Australia","startDate":"2014-10-01","conditions":"Melanoma","enrollment":35},{"nctId":"NCT07256184","phase":"","title":"Prognostic and Treatment-Response Factors in Metastatic Melanoma: Multi-Center Analysis","status":"COMPLETED","sponsor":"Ankara Etlik City Hospital","startDate":"2022-11-15","conditions":"Metastatic Malignant Melanoma","enrollment":232},{"nctId":"NCT04961619","phase":"","title":"Adjuvant Dabrafenib and Trametinib Treatment in Patients With Completely Resected High-risk Stage III Melanoma.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-12-01","conditions":"Melanoma","enrollment":39},{"nctId":"NCT03149029","phase":"PHASE2","title":"Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2017-11-27","conditions":"Metastatic Melanoma","enrollment":16},{"nctId":"NCT04940052","phase":"PHASE3","title":"Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2021-11-15","conditions":"Differentiated Thyroid Cancer (DTC)","enrollment":153},{"nctId":"NCT04116541","phase":"PHASE2","title":"A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.","status":"RECRUITING","sponsor":"Centre Leon Berard","startDate":"2020-01-28","conditions":"Malignant Solid Tumor","enrollment":455},{"nctId":"NCT03975231","phase":"PHASE1","title":"Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2020-09-14","conditions":"BRAF NP_004324.2:p.V600E, BRAF V600K Mutation Present, Thyroid Gland Anaplastic Carcinoma","enrollment":6},{"nctId":"NCT04544111","phase":"PHASE2","title":"PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-09-02","conditions":"Thyroid Cancer, Thyroid Cancer, Follicular, Papillary Thyroid Cancer","enrollment":19},{"nctId":"NCT06967155","phase":"PHASE2","title":"A Study of Irinotecan With Dabrafenib Plus Trametinib and Anti-EGFR in the Second Line of Therapy in People With Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Blokhin's Russian Cancer Research Center","startDate":"2025-03-01","conditions":"Neoplasms","enrollment":23},{"nctId":"NCT02967692","phase":"PHASE3","title":"A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-02-17","conditions":"Melanoma","enrollment":568},{"nctId":"NCT07092670","phase":"","title":"MELAFERT: Impact of Adjuvant Therapy on FERTility in Patients With Resected MELAnoma at High Risk of Relapse.","status":"RECRUITING","sponsor":"Intergruppo Melanoma Italiano","startDate":"2025-08-04","conditions":"Melanoma, Fertility","enrollment":270},{"nctId":"NCT01723202","phase":"PHASE2","title":"Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer","status":"COMPLETED","sponsor":"Bhavana Konda","startDate":"2012-11-07","conditions":"Follicular Thyroid Cancer, Insular Thyroid Cancer, Papillary Thyroid Cancer","enrollment":53},{"nctId":"NCT06195228","phase":"PHASE4","title":"A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2020-01-01","conditions":"Advanced Thyroid Cancer Patients Who Received Target Therapy","enrollment":800},{"nctId":"NCT04238624","phase":"PHASE2","title":"Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-01-20","conditions":"Anaplastic Thyroid Cancer, Thyroid Cancer, BRAF Gene Mutation","enrollment":16},{"nctId":"NCT07022834","phase":"PHASE2","title":"Real-world Study of Darafenib or Trametinib and Clofarabine for High-risk/Recurrent/Refractory Langerhans Cell Histiocytosis in Children","status":"RECRUITING","sponsor":"West China Second University Hospital","startDate":"2025-06-01","conditions":"Langerhans Cell Histiocytosis (LCH)","enrollment":20},{"nctId":"NCT07010393","phase":"PHASE4","title":"Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study","status":"NOT_YET_RECRUITING","sponsor":"Fujian Medical University","startDate":"2025-07-01","conditions":"Thyroid Neoplasms","enrollment":335},{"nctId":"NCT06712875","phase":"PHASE1, PHASE2","title":"MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas","status":"RECRUITING","sponsor":"Ann & Robert H Lurie Children's Hospital of Chicago","startDate":"2025-04-01","conditions":"Low Grade Glioma, High Grade Glioma","enrollment":27},{"nctId":"NCT03551626","phase":"PHASE3","title":"Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-08-29","conditions":"Malignant Melanoma","enrollment":552},{"nctId":"NCT03944356","phase":"","title":"BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients","status":"COMPLETED","sponsor":"EuMelaReg gGmbH","startDate":"2019-07-01","conditions":"Melanoma","enrollment":232},{"nctId":"NCT06819605","phase":"PHASE2, PHASE3","title":"Neoadjuvant Therapy With Conservative Surgery vs. Up-front Conservative Surgery for BRAF V600E-Mutated Ameloblastoma","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","startDate":"2025-03-01","conditions":"Ameloblastoma","enrollment":46},{"nctId":"NCT03026517","phase":"PHASE1","title":"Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-01","conditions":"Melanoma","enrollment":18},{"nctId":"NCT02872259","phase":"PHASE1, PHASE2","title":"BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma","status":"COMPLETED","sponsor":"Haukeland University Hospital","startDate":"2017-02-13","conditions":"Melanoma","enrollment":74},{"nctId":"NCT01902173","phase":"PHASE1, PHASE2","title":"Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2013-10-08","conditions":"Hematopoietic and Lymphoid Cell Neoplasm, Locally Advanced Malignant Solid Neoplasm, Locally Advanced Melanoma","enrollment":27},{"nctId":"NCT06739395","phase":"PHASE2","title":"Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion","status":"RECRUITING","sponsor":"Tianjin Medical University Second Hospital","startDate":"2024-11-01","conditions":"Solid Tumor, Precision Medicine","enrollment":300},{"nctId":"NCT06563999","phase":"PHASE2","title":"Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-11-01","conditions":"Lung Cancer Stage III, Mutation","enrollment":120},{"nctId":"NCT02392871","phase":"PHASE1, PHASE2","title":"Radiotherapy & Combi in Metastatic Melanoma","status":"COMPLETED","sponsor":"Melanoma and Skin Cancer Trials Limited","startDate":"2015-05","conditions":"Metastatic Melanoma","enrollment":10},{"nctId":"NCT04507919","phase":"","title":"Managed Access Program Cohort Treatment Plan CTMT212X2002I to Provide Access to Trametinib and Dabrafenib Combination Therapy for Patients With BRAF V600 Mutation-positive Advanced Non-Small Cell Lung Cancer","status":"NO_LONGER_AVAILABLE","sponsor":"Novartis Pharmaceuticals","startDate":"","conditions":"Small Cell Lung Carcinoma","enrollment":""},{"nctId":"NCT04652258","phase":"PHASE2","title":"Pyrexia Management Using an IL-6 Antibody in BRAF+ Melanoma Patients Treated with Dabrafenib/ Trametinib +/- Immunotherapy","status":"TERMINATED","sponsor":"University of Zurich","startDate":"2021-02-01","conditions":"Pyrexia","enrollment":20},{"nctId":"NCT06653517","phase":"PHASE2","title":"Clinical Study of Neoadjuvant Targeted Therapy for Ameloblastoma","status":"RECRUITING","sponsor":"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","startDate":"2023-01-01","conditions":"Ameloblastoma, BRAF V600E Mutation Positive","enrollment":12},{"nctId":"NCT02097225","phase":"PHASE1","title":"Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2014-05-29","conditions":"BRAF V600E Mutation Present, BRAF V600K Mutation Present, Metastatic Malignant Solid Neoplasm","enrollment":22},{"nctId":"NCT06557291","phase":"","title":"Relapse-Free Survival With Adjuvant Dabrafenib/Trametinib Therapy in Patients With BRAF V600-mutated Stage III/IV Melanoma","status":"COMPLETED","sponsor":"Novartis","startDate":"2022-10-04","conditions":"BRAF V600 Mutated-Stage III/IV Melanoma","enrollment":38},{"nctId":"NCT06532149","phase":"","title":"ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer","status":"RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2024-08-05","conditions":"NSCLC Stage IV, Sex Disorder, Hypogonadism, Male","enrollment":80},{"nctId":"NCT03455764","phase":"PHASE1, PHASE2","title":"MCS110 With BRAF/MEK Inhibition in Patients With Melanoma","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2018-09-10","conditions":"Melanoma","enrollment":6},{"nctId":"NCT05159245","phase":"PHASE2","title":"The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs","status":"RECRUITING","sponsor":"Helsinki University Central Hospital","startDate":"2021-12-10","conditions":"Advanced Cancer, Solid Tumor, Haematological Malignancy","enrollment":250},{"nctId":"NCT06362694","phase":"PHASE2","title":"Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy","status":"RECRUITING","sponsor":"Saint Petersburg State University, Russia","startDate":"2024-03-25","conditions":"Anaplastic Thyroid Cancer","enrollment":10},{"nctId":"NCT06337617","phase":"","title":"A Multi-center Retrospective Study With Secondary Use of Data of Tafinlar (Dabrafenib) Plus Mekinist (Trametinib) in Chinese Patients With BRAF V600 Mutation Positive Melanoma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2022-05-10","conditions":"BRAF V600 Mutation Positive Melanoma","enrollment":90},{"nctId":"NCT04949113","phase":"PHASE3","title":"Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2021-07-08","conditions":"Malignant Melanoma Stage III","enrollment":423},{"nctId":"NCT03878524","phase":"PHASE1","title":"Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2020-04-01","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia","enrollment":2},{"nctId":"NCT04817956","phase":"PHASE2","title":"Improving Public Cancer Care by Implementing Precision Medicine in Norway","status":"RECRUITING","sponsor":"Oslo University Hospital","startDate":"2021-04-01","conditions":"Cancer Metastatic","enrollment":3000},{"nctId":"NCT05525273","phase":"PHASE2","title":"Treatment of BRAF ( B-Rapidly Accelerated Fibrosarcoma) Mutated Papillary Craniopharyngioma","status":"RECRUITING","sponsor":"Eva Marie Erfurth, MD, PhD","startDate":"2023-09-01","conditions":"Craniopharyngioma","enrollment":25},{"nctId":"NCT02367859","phase":"PHASE2","title":"Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma","status":"COMPLETED","sponsor":"Stanford University","startDate":"2017-07-17","conditions":"Ameloblastoma, BRAF Gene Mutation","enrollment":1},{"nctId":"NCT02925234","phase":"PHASE2","title":"The Drug Rediscovery Protocol (DRUP Trial)","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2016-08","conditions":"Cancer, Tumors, Neoplasm","enrollment":1550},{"nctId":"NCT05432622","phase":"","title":"A Study of Treatment Patterns and Outcomes in Participants With Stage IIIA Melanoma Receiving Adjuvant Systemic Therapy","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2019-12-19","conditions":"Melanoma","enrollment":95},{"nctId":"NCT02684058","phase":"PHASE2","title":"Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-12-28","conditions":"Diffuse Astrocytoma, Anaplastic Astrocytoma, Astrocytoma","enrollment":151},{"nctId":"NCT02382549","phase":"EARLY_PHASE1","title":"A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib","status":"TERMINATED","sponsor":"Craig L Slingluff, Jr","startDate":"2016-04","conditions":"Melanoma","enrollment":8},{"nctId":"NCT05876806","phase":"PHASE2","title":"Dabrafenib Plus Trametinib in Patients With Advanced Solid Tumor Having BRAF V600E Mutation or Clinically Actionable BRAF Gene Alterations","status":"RECRUITING","sponsor":"Se Jun Park","startDate":"2023-06-20","conditions":"Cancer","enrollment":30},{"nctId":"NCT05182931","phase":"PHASE2","title":"A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study)","status":"UNKNOWN","sponsor":"Olivia Newton-John Cancer Research Institute","startDate":"2022-07-14","conditions":"Thyroid Cancer","enrollment":80},{"nctId":"NCT05370807","phase":"PHASE2","title":"A Clinical Trial of Regorafenib in Patients With Pretreated Advanced Melanoma","status":"UNKNOWN","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2022-10-03","conditions":"Melanoma Stage III, Melanoma Stage IV","enrollment":48},{"nctId":"NCT05988697","phase":"","title":"Evaluate the Efficacy and Safety of Aspirin in Combination With Trametinib and Dabrafenib","status":"NOT_YET_RECRUITING","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2023-11-01","conditions":"NSCLC, BRAF V600E Mutation, Advanced Cancer","enrollment":36},{"nctId":"NCT06079333","phase":"PHASE2","title":"NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2023-01-01","conditions":"Anaplastic Thyroid Cancer","enrollment":20},{"nctId":"NCT06054191","phase":"PHASE2","title":"Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 Mutations","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-02-01","conditions":"NSCLC, BRAF V600 Mutation, MET Exon 14 Mutation","enrollment":40},{"nctId":"NCT04059224","phase":"PHASE2","title":"TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma","status":"COMPLETED","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2019-01-28","conditions":"Stage IV Melanoma, Stage III Melanoma","enrollment":45},{"nctId":"NCT03272464","phase":"PHASE1","title":"INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.","status":"TERMINATED","sponsor":"Massachusetts General Hospital","startDate":"2019-05-29","conditions":"Melanoma","enrollment":1},{"nctId":"NCT05299580","phase":"PHASE2","title":"\"Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)\"","status":"WITHDRAWN","sponsor":"Fondazione Melanoma Onlus","startDate":"2021-02-18","conditions":"Melanoma","enrollment":""},{"nctId":"NCT02858921","phase":"PHASE2","title":"Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma","status":"UNKNOWN","sponsor":"Melanoma Institute Australia","startDate":"2017-11-08","conditions":"Melanoma","enrollment":60},{"nctId":"NCT01682083","phase":"PHASE3","title":"Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-01-08","conditions":"Melanoma","enrollment":870},{"nctId":"NCT03808441","phase":"PHASE2","title":"CAcTUS - Circulating Tumour DNA Guided Switch","status":"UNKNOWN","sponsor":"The Christie NHS Foundation Trust","startDate":"2019-05-02","conditions":"Melanoma","enrollment":21},{"nctId":"NCT02034110","phase":"PHASE2","title":"Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-03-12","conditions":"Cancer","enrollment":206},{"nctId":"NCT03563729","phase":"PHASE2","title":"Melanoma Metastasized to the Brain and Steroids","status":"RECRUITING","sponsor":"Inge Marie Svane","startDate":"2018-06-06","conditions":"Malignant Melanoma","enrollment":80},{"nctId":"NCT04619316","phase":"PHASE2","title":"Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancers With MAPK Inhibition","status":"UNKNOWN","sponsor":"University Hospital, Essen","startDate":"2018-02-05","conditions":"Metastatic Thyroid Cancer","enrollment":70},{"nctId":"NCT04547946","phase":"","title":"Observational Study for Melanoma Adjuvant Treatment With Tafinlar® + Mekinist® (Dabrafenib + Trametinib)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-10-15","conditions":"Malignant Melanoma","enrollment":3},{"nctId":"NCT05848219","phase":"","title":"Healthcare Resource Utilization and Costs in Metastatic Melanoma Patients Initiated Dabrafenib + Trametinib and Encorafenib + Binimetinib","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-10-16","conditions":"Metastatic Melanoma","enrollment":543},{"nctId":"NCT05611229","phase":"","title":"Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-06-16","conditions":"Metastatic Melanoma","enrollment":1975},{"nctId":"NCT04775095","phase":"","title":"BRAF V600-mutated Lung Carcinoma Treated With the Combination of Dabrafenib-trametinib: a Retrospective Evaluation","status":"COMPLETED","sponsor":"Intergroupe Francophone de Cancerologie Thoracique","startDate":"2021-03-08","conditions":"Non Small Cell Lung Cancer, BRAF V600 Mutation","enrollment":163},{"nctId":"NCT02130466","phase":"PHASE1, PHASE2","title":"A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-05-29","conditions":"Melanoma, Solid Tumors","enrollment":184},{"nctId":"NCT02551718","phase":"NA","title":"High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia","status":"COMPLETED","sponsor":"University of Washington","startDate":"2015-09-11","conditions":"Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia","enrollment":34},{"nctId":"NCT03668431","phase":"PHASE2","title":"Dabrafenib + Trametinib + PDR001 In Colorectal Cancer","status":"UNKNOWN","sponsor":"Massachusetts General Hospital","startDate":"2018-10-15","conditions":"Metastatic Colorectal Cancer","enrollment":25},{"nctId":"NCT05171374","phase":"","title":"pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE","status":"UNKNOWN","sponsor":"MelanomaPRO, Russia","startDate":"2021-09-30","conditions":"Melanoma Stage III, Melanoma Stage IV, Melanoma","enrollment":500},{"nctId":"NCT01336634","phase":"PHASE2","title":"Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-08-05","conditions":"Cancer","enrollment":177},{"nctId":"NCT01940809","phase":"PHASE1","title":"Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2013-08-28","conditions":"BRAF V600E Mutation Present, BRAF V600K Mutation Present, Metastatic Melanoma","enrollment":15},{"nctId":"NCT02083354","phase":"PHASE2","title":"Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-03-18","conditions":"Cancer, Melanoma","enrollment":77},{"nctId":"NCT02257424","phase":"PHASE1, PHASE2","title":"Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma","status":"COMPLETED","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2014-10","conditions":"Advanced BRAF Mutant Melanoma","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":272,"recentPublications":[{"date":"2026 Mar 11","pmid":"41830662","title":"BRAF(V600E)-mutated central nervous system tumors benefit from treatment with dabrafenib plus trametinib: Results from the Drug Rediscovery Protocol.","journal":"European journal of cancer (Oxford, England : 1990)"},{"date":"2026 Feb 18","pmid":"41749920","title":"COMBI-EU: Real-World Evidence on Adverse Event Management and Time on Therapy with Adjuvant Dabrafenib Plus Trametinib in Patients with BRAF V600-Mutant Melanoma.","journal":"Cancers"},{"date":"2026 Feb 25","pmid":"41740060","title":"Cost-Effectiveness of Dabrafenib Plus Trametinib Versus Standard Chemotherapy in BRAFV600E-Mutant Pediatric Low-Grade Glioma.","journal":"JCO oncology practice"},{"date":"2026 Apr 1","pmid":"41691529","title":"Determinants of adjuvant treatment choice between immunotherapy (immune checkpoint inhibitor) and targeted therapy in resected stage III BRAF V600-mutated cutaneous melanoma: a multicenter observational study: MELADJ3.","journal":"Melanoma research"},{"date":"2026 Feb 10","pmid":"41663623","title":"Clinical efficacy and cardiac toxicity associated with first-line dabrafenib plus trametinib in advanced BRAF V600_K601delinsE-mutated lung adenocarcinoma: a case report and literature review.","journal":"Discover oncology"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Dabrafenib plus Trametinib","genericName":"dabrafenib-plus-trametinib","companyName":"Pfizer Inc.","companyId":"pfizer","modality":"","firstApprovalDate":"","aiSummary":"","enrichmentLevel":5,"visitCount":7,"trialStats":{"total":20,"withResults":12},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T08:45:49.749565+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":false,"safety":true,"trials":true,"score":3}}